- History and physical examination
- Endometrial biopsy or curettings to confirm the diagnosis
- MMR, p53 and estrogen receptor (ER) immunohistochemistry to be performed on ALL endometrial cancer biopsies of all histotypes.
This should be available in any pathology laboratory and is now considered standard of care for all ECs in BC
- CA 125 (can be elevated with extra-uterine disease)
- CT chest/abdo/pelvis is required for any one of the following:
- Grade 3 and/or non-endometrioid histology
- Clinical history of patient symptoms and or examination suggests disease spread beyond the uterus (>Stage I)
- Elevated CA125 not otherwise explained
All patients with potential clinical involvement of the cervix should be referred for assessment regarding possible surgical staging. Patients who are deemed to have inoperable disease by the gynecologic oncology team will be referred for neoadjuvant chemotherapy (see
section 6.B below).
We recommend all patients referred to BC Cancer have a pathology review.
